Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 163.09M |
| Revenue (ttm) | 15.00M |
| Net Income (ttm) | -44.35M |
| Shares Out | 29.93M |
| EPS (ttm) | -1.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,436 |
| Open | 5.51 |
| Previous Close | 5.63 |
| Day's Range | 5.41 - 5.60 |
| 52-Week Range | 3.98 - 8.24 |
| Beta | 3.51 |
| Analysts | Buy |
| Price Target | 14.48 (+165.7%) |
| Earnings Date | May 16, 2022 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophyla...
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is 14.48, which is an increase of 165.69% from the latest price.
News
Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
MONTREAL and CHARLOTTE, N.C., May 17, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update
- RAPID topline data readout remains on track for mid-second half 2022 - Results from NODE-302 study highlights etripamil safety and reduced need for ED interventions MONTREAL and CHARLOTTE,...
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment o...
- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention - - As in other studies, etripamil was well tolerated by patients - - Data to be featured during ...
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., April 15, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT
Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler, MD and Sean Pokorney, MD Conference call and webcast on Thursday, April 21, 2022 at 1:00 p.m. ET MONTREAL and CHARLOTTE, N.C.
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corpo...
- RAPID topline data readout expected mid-second half 2022 MONTREAL and CHARLOTTE, N.C., March 24, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company f...
Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
MONTREAL and CHARLOTTE, N.C., March 1, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer
MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
MONTREAL and CHARLOTTE, N.C., Jan. 4, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients wi...
- Etripamil significantly decreased heart rate during SVT episodes and independent of conversion to SR – - HR changes occurred within 5 minutes and were sustained for 60 minutes – - Data presented at AH...
Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 12, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
MONTREAL and CHARLOTTE, N.C., Sept. 22, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
MONTREAL and CHARLOTTE, N.C., Sept. 7, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Aug. 11, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., May 26, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China
Milestone Pharmaceuticals Inc (NASDAQ: MIST) hit a major snag last March when its investigational etripamil nasal spray for episodes of rapid heart rate missed the primary endpoint. A year later, it's t...
Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21
- Statistically Significant Improvements in PSVT-Associated Symptoms and Less ER Visits Observed in Patients Treated with Etripamil Compared to Placebo in the NODE-301 Trial - - Data Presented at the Am...
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corpora...
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercia...
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardi...
Milestone Pharmaceuticals Stock Is a Bet On Etripamil
If Milestone Pharmaceuticals' Etripamil nasal spray succeeds in clinical trials, MIST stock is going to see big growth. The post Milestone Pharmaceuticals Stock Is a Bet On Etripamil appeared first on I...
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical and Corpo...
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atr...
MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative car...
Milestone Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Corporate Update
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative card...
Milestone Pharmaceuticals Announces Pricing of a Public Offering of $45 Million of Common Shares and Pre-Funded Warrants
MONTREAL and CHARLOTTE, N.C., Oct. 23, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
MONTREAL and CHARLOTTE, N.C., Oct. 22, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing ...